|
Video: What is a Stock Split?
|
|
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Co.'s multi-therapeutic pipeline has a primary focus on neurodegeneration and its primary program utilizing IkT-148009, c-Abl inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. Co. is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients. According to our IKT split history records, Inhibikase Therapeutics has had 1 split. | |
|
Inhibikase Therapeutics (IKT) has 1 split in our IKT split history database. The split for IKT took place on June 30, 2023. This was a 1 for 6 reverse split, meaning for each 6 shares of IKT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as Inhibikase Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the IKT split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Inhibikase Therapeutics shares, starting with a $10,000 purchase of IKT, presented on a split-history-adjusted basis factoring in the complete IKT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/24/2020 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$58.80 |
|
End price/share: |
$2.10 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.43% |
|
Average Annual Total Return: |
-63.40% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$357.20 |
|
Years: |
3.32 |
|
|
|
Date |
Ratio |
06/30/2023 | 1 for 6 |
|
|